M
Meredith L. Stone
Researcher at University of Pennsylvania
Publications - 5
Citations - 324
Meredith L. Stone is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Tumor microenvironment & Metastasis. The author has an hindex of 3, co-authored 5 publications receiving 190 citations. Previous affiliations of Meredith L. Stone include Johns Hopkins University.
Papers
More filters
Journal ArticleDOI
Hepatocytes direct the formation of a pro-metastatic niche in the liver
Jae W. Lee,Meredith L. Stone,Paige M. Porrett,Stacy K. Thomas,Chad A. Komar,Joey H. Li,Devora Delman,Kathleen Graham,Whitney L. Gladney,Xia Hua,Taylor A. Black,Austin L. Chien,Krishna S. Majmundar,Jeffrey C. Thompson,Stephanie S. Yee,Mark H. O'Hara,Charu Aggarwal,Dong Xin,Abraham Shaked,Mingming Gao,Dexi Liu,Mitesh J. Borad,Ramesh K. Ramanathan,Ramesh K. Ramanathan,Erica L. Carpenter,Ailing Ji,Maria C. de Beer,Frederick C. de Beer,Nancy R. Webb,Gregory L. Beatty +29 more
TL;DR: It is shown that hepatocytes coordinate myeloid cell accumulation and fibrosis within the liver and, in doing so, increase the susceptibility of the liver to metastatic seeding and outgrowth.
Journal ArticleDOI
DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer
Meghan Travers,Stephen M. Brown,Matthew Dunworth,Cassandra E. Holbert,Karla R. Wiehagen,Kurtis E. Bachman,Jackson R. Foley,Meredith L. Stone,Meredith L. Stone,Stephen B. Baylin,Robert A. Casero,Cynthia A. Zahnow +11 more
TL;DR: The combination therapy had a striking increase in survival when compared to single agent treatment, despite a smaller difference in recruited lymphocytes, and observations suggest the novel combination therapy modifies macrophage polarization in the tumor microenvironment, recruiting M1 macrophages and prolonging survival.
Journal ArticleDOI
Cellular determinants and therapeutic implications of inflammation in pancreatic cancer.
TL;DR: The current understanding of key determinants of inflammation in PDAC is described; mechanisms by which inflammation drives immune suppression; the impact of inflammation on metastasis, therapeutic resistance, and clinical outcomes; and strategies to intervene on inflammation for providing therapeutic benefit are described.
Journal ArticleDOI
TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy.
Meredith L. Stone,Jesse Lee,Veronica M. Herrera,Kathleen Graham,Jae W. Lee,Austin P. Huffman,Heather Coho,Evan Tooker,Max I Myers,Michael A. Giannone,Yan Li,Thomas H. Buckingham,Kristen B. Long,Gregory L. Beatty +13 more
TL;DR: In this paper, a mechanistic link between cytokine release and hepatotoxicity induced by anti-CD40 when combined with chemotherapy was reported and showed that toxicity can be suppressed without impairing therapeutic efficacy.
Proceedings ArticleDOI
Abstract 115: A CD40 agonist potentiates the efficacy and immune-stimulatory capacity of chemotherapy in combination with a focal adhesion kinase inhibitor in a mouse model of pancreatic ductal adenocarcinoma
Meredith L. Stone,Kathleen Graham,Daniel L. Aldridge,Kanika Jain,Xiaoqing Pan,Jonathan Pachter,Gregory L. Beatty +6 more
TL;DR: Stone et al. as mentioned in this paper found that CD40-dependent innate immune responses can disrupt the stromal matrix that surrounds the tumor and sensitize tumors to the cytotoxic and immune-stimulatory effects of chemotherapy.